RUNX3 and head and neck squamous cell carcinoma: Control and RUNX3 overexpressing HSC3 cells were exposed for 72 hours to adriamycin (DOX; 0.5 and 1 μg/ml), which is a chemotherapeutic agent commonly used in the treatment of HNSCC.